Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma : Systematic review of 42 studies published 2008-2018
Journal article
MacDonald, Karen M., Kavati, Abhishek, Ortiz, Benjamin, Alhossan, Abdulaziz, Lee, Christopher S. and Abraham, Ivo. (2019). Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma : Systematic review of 42 studies published 2008-2018. Expert Review of Clinical Immunology. 15(5), pp. 553-569. https://doi.org/10.1080/1744666X.2019.1574571
Authors | MacDonald, Karen M., Kavati, Abhishek, Ortiz, Benjamin, Alhossan, Abdulaziz, Lee, Christopher S. and Abraham, Ivo |
---|---|
Abstract | Introduction: Omalizumab is a recombinant monoclonal anti-IgE antibody approved in the US as add-on treatment in moderate-to-severe allergic asthma (in severe allergic asthma [SAA] in Europe). A 2016 review of 24 real-world effectiveness studies in SAA published between 2008–2015 concluded that omalizumab was associated with significant improvements in objective and subjective outcomes with benefits extending beyond 2 years. Several new real-world studies have been published since, bringing the total to 42 studies. Areas covered: This systematic review of 42 studies published since 2008 updates and extends the 2016 review on the real-word evidence on omalizumab in SAA. It offers greater granularity as to time windows within which outcomes are reported and includes studies extending well beyond 4 years post omalizumab initiation. Expert commentary: This review firmly establishes the short-term effectiveness of omalizumab in adolescent and adult patients with SAA at 1 year, and provides strong evidence of long-term effectiveness up to 4 years and emergent evidence of effectiveness beyond 4 years. In the aggregate, these 42 studies underscore the long-term effectiveness of omalizumab in terms of: reducing exacerbations and symptoms, achieving asthma control, improving lung function, enhancing quality of life, decreasing emergency department visits and hospitalizations, and promoting concomitant medication-sparing. |
Keywords | allergic asthma; IgE; omalizumab; real-word effectiveness; systematic review |
Year | 2019 |
Journal | Expert Review of Clinical Immunology |
Journal citation | 15 (5), pp. 553-569 |
Publisher | Taylor and Francis Ltd |
ISSN | 1744-666X |
Digital Object Identifier (DOI) | https://doi.org/10.1080/1744666X.2019.1574571 |
Scopus EID | 2-s2.0-85064169866 |
Open access | Published as ‘gold’ (paid) open access |
Research or scholarly | Research |
Page range | 553-569 |
Publisher's version | License File Access Level Open |
Output status | Published |
Publication dates | |
Online | 14 Feb 2019 |
Publication process dates | |
Accepted | 23 Jan 2019 |
Deposited | 02 Sep 2021 |
https://acuresearchbank.acu.edu.au/item/8wv22/short-and-long-term-real-world-effectiveness-of-omalizumab-in-severe-allergic-asthma-systematic-review-of-42-studies-published-2008-2018
Download files
Publisher's version
OA_MacDonald_2019_Short_and_long_term_real_world.pdf | |
License: CC BY-NC-ND 4.0 | |
File access level: Open |
85
total views50
total downloads1
views this month2
downloads this month